700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Review Article Open Access
The diagnosis of the Alzheimer Disease if rendered accurately today and in the foreseeable future, comes with it a disease course that is inalterable and with no hope of cure After the expansion of the molecular technology and with more than 100 years of identification of hallmark lesions of AD still there is absence of, or fundamentally erraneous understanding of AD pathogenesis. Hence there is absence of disease modifying therapy of AD. We are compelled to accept that modern science has provided a catalog of downstream changes in AD. These changes include: Amyloidosis; tau phosphorylation; oxidative stress including RNA modification and heavy metal toxicity; neurotrophic and neurogeneration failure; disordered energy metabolism; synaptic alteration; and autophagy. In this review we examine this aspect in the light of available evidences present in the literature. Furthermore pathology and pathophysiology of AD based on the recent observations is also described. A critical analysis of possible ABP transport across BBB is presented; animal models of AD are given in brief. Furthermore a new role of nano drug delivery to treat the AD is also discussed. Over 35000 plant species are currently used for medicinal purposes around the world. These plant contain more than 4000 flavanoid structures, terpenes, alkaloids, etc and provide numerous health benefits including anti-inflammatory, anti-oxidant, anti neoplastic, anti diabetic. Can we Identify the herbal extracts that affect AD pathomechanism, highlighting interaction of A β, mitochondrial anti-oxidant mechanism, inflammatory pathway, and cholinergic and glutaminergic function in pre synaptic and post synaptic neuron.This is a big question. Also Is Juglans regia (walnut) one such alternative?
To read the full article Peer-reviewed Article PDF
Author(s): Ashna Kohli, Preeti Kothiyal
Alzheimerâs disease, amyloidosis, BBB, juglans regia, nano drug delivery, tau phosphorylation, Alzheimer Disease